JANX vs URGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
JANX · Janux Therapeutics$17.63 ▲ 9.78%
URGN · UroGen Pharma Ltd$24.75 ▼ 3.81%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- JANX -36.1%
- URGN +7.0%
Head to head
| Metric | JANX | URGN |
|---|---|---|
| Price | $17.63 | $24.75 |
| Change today | ▲ 9.78% | ▼ 3.81% |
| Market cap | $1.08B | $1.21B |
| Return, 3 months | +7.4% | -46.6% |
| Return, year to date | +27.8% | +5.7% |
| Return, 1 year | -33.4% | +6.5% |
| P/E (TTM) | -11.1 | -18.9 |
| P/B | 1.2 | -9.7 |
| P/E percentile vs own 5y | 48th | 5th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +199.2% |
| Net profit growth (YoY) | +35.1% | +71.3% |
| Gross margin | – | 90.8% |
| Operating margin | -598.1% | -35.3% |
| Net margin | -427.5% | -51.7% |
| Return on equity | -10.7% | – |
| Analyst target vs. price | +89.4% | +143.2% |
| Analyst buy share | 91% | 80% |
| RSI (14) | 52 | 18 |
| 30-day volatility | 61.4% | 72.8% |
| Max drawdown, 1 year | -64.9% | -50.8% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- URGN is the largest of the group by market value.
- URGN has returned the most over the past year.
- URGN carries the lowest trailing P/E.
- URGN keeps the most profit per dollar of sales.
- JANX has been the calmest stock over the last 30 days.